Testosterone replacement therapy has been practiced in some form since the 1940s, and the clinical indications for it — classical hypogonadism, whether primary or secondary — are well established in the endocrinology literature. What has happened to TRT in the past two decades is something different: the gradual expansion of indication, the lowering of diagnostic thresholds, and the emergence of a direct-to-consumer clinical infrastructure that has made testosterone prescribing accessible to men whose testosterone levels fall within the normal reference range but who experience symptoms they attribute to “low T.” The clinical, economic, and cultural dimensions of this expansion are intertwined in ways that resist clean separation.
The Diagnostic Threshold Problem
The diagnostic threshold for hypogonadism in clinical practice is contested in ways that create substantial prescribing latitude. Laboratory reference ranges for total testosterone are established from population distributions that include older men whose testosterone has declined with age — which means a level that is “normal” by reference range standards may nonetheless represent a significant decline from that individual’s peak and may correlate with symptomatic burden. The Endocrine Society guidelines for testosterone therapy have historically emphasized a total testosterone threshold below 300 ng/dL in the presence of clinical symptoms, but the direct-to-consumer TRT market has operationalized more permissive diagnostic criteria, and telemedicine platforms have made access to physicians willing to prescribe at higher levels considerably easier.
The clinical evidence for testosterone therapy in men with low-normal or borderline levels — rather than in men with classical hypogonadism — is considerably more ambiguous than the marketing implies. The Testosterone Trials, a coordinated set of clinical trials funded by the NIH and published between 2016 and 2018, found modest benefits of testosterone replacement in older men with confirmed low testosterone across several domains — sexual function, physical performance, anemia correction — alongside a signal of increased cardiovascular events that the trials were underpowered to fully characterize. The cardiovascular safety question remains incompletely resolved, with observational data producing conflicting signals that the field has not reconciled.
Growth Hormone and Its Clinical Complexity
Human growth hormone therapy in adults is clinically indicated for growth hormone deficiency — a documented hypothalamic-pituitary axis disorder that produces a specific metabolic phenotype and responds to replacement therapy in established ways. The off-label use of HGH for body composition improvement, recovery enhancement, and anti-aging in individuals without documented deficiency is pharmacologically active — HGH is not inert in eudeficient individuals — but its effects in this population are more modest than the optimization market represents, and the long-term safety profile of supraphysiologic GH administration is genuinely uncertain. The relationship between HGH and cancer risk, in particular, has been debated in the endocrinology literature for decades without resolution, driven by the biological plausibility of IGF-1’s mitogenic effects and the inadequacy of available epidemiological data to estimate the magnitude of risk at the doses used in optimization protocols.
The growth hormone secretagogue approach — using peptides like sermorelin, ipamorelin, or tesamorelin to stimulate endogenous GH release rather than administering exogenous HGH — has appeal as a pharmacological strategy that preserves the pulsatile dynamics of natural GH secretion and avoids the direct exogenous GH regulatory constraints. The actual clinical benefit of this approach, relative to direct HGH administration or to no intervention, is not established by clinical trial evidence at a level that would satisfy conventional regulatory standards. The optimization community’s enthusiasm for secretagogues reflects their theoretical advantages and their compounding pharmacy accessibility rather than a superior evidence base.
The Cultural Economy of Male Optimization
The male optimization market is not simply a clinical phenomenon — it is a cultural one, shaped by the intersection of masculinity, aging anxiety, and a wellness culture that has normalized the active management of biological processes that previous generations treated as natural decline. The market that has emerged to serve this demand is heterogeneous: it includes academically credentialed sports medicine and endocrinology physicians practicing evidence-based hormonal optimization within established guidelines, functional medicine practitioners applying more permissive interpretive frameworks, and direct-to-consumer platforms whose clinical oversight ranges from adequate to nominal. Distinguishing between these categories requires sophistication that most patients — and most policy frameworks — have not developed. The cultural legitimacy of optimization medicine has outrun the regulatory and clinical infrastructure needed to govern it.
